PH30245A - Hydroxamic derivatives and pharmaceutical compositions - Google Patents
Hydroxamic derivatives and pharmaceutical compositionsInfo
- Publication number
- PH30245A PH30245A PH46328A PH46328A PH30245A PH 30245 A PH30245 A PH 30245A PH 46328 A PH46328 A PH 46328A PH 46328 A PH46328 A PH 46328A PH 30245 A PH30245 A PH 30245A
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical compositions
- heterocyclic ring
- represent hydrogen
- membered
- hydroxamic derivatives
- Prior art date
Links
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002442 collagenase inhibitor Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929212421A GB9212421D0 (en) | 1992-06-11 | 1992-06-11 | Hydroxamic acid derivatives |
| GB939305720A GB9305720D0 (en) | 1992-06-11 | 1993-03-19 | Hydroxamic acid derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH30245A true PH30245A (en) | 1997-02-05 |
Family
ID=26301054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH46328A PH30245A (en) | 1992-06-11 | 1993-06-10 | Hydroxamic derivatives and pharmaceutical compositions |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5318964A (de) |
| EP (1) | EP0574758B1 (de) |
| JP (1) | JPH0776210B2 (de) |
| CN (1) | CN1035616C (de) |
| AT (1) | ATE170840T1 (de) |
| AU (1) | AU659555B2 (de) |
| BG (1) | BG61724B1 (de) |
| CA (1) | CA2098168A1 (de) |
| CZ (1) | CZ283373B6 (de) |
| DE (1) | DE69320869T2 (de) |
| DK (1) | DK0574758T3 (de) |
| ES (1) | ES2121896T3 (de) |
| FI (1) | FI109535B (de) |
| HU (1) | HU9301645D0 (de) |
| IL (1) | IL105921A (de) |
| IS (1) | IS4031A (de) |
| MY (1) | MY108798A (de) |
| NO (1) | NO932117L (de) |
| NZ (1) | NZ247765A (de) |
| PH (1) | PH30245A (de) |
| SK (1) | SK57393A3 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5530161A (en) * | 1991-07-08 | 1996-06-25 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors |
| BR9506535A (pt) * | 1994-01-20 | 1997-09-16 | British Biotech Pharm | Inibidores de metaloproteinases |
| GB9501737D0 (en) * | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
| WO1995029892A1 (en) * | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
| GB9411598D0 (en) * | 1994-06-09 | 1994-08-03 | Hoffmann La Roche | Hydroxamic acid derivatives |
| GB9423914D0 (en) * | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
| US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
| US5691381A (en) * | 1995-04-18 | 1997-11-25 | The Dupont Merck Pharmaceutical Company | Hydroxamic and carbocyclic acids as metalloprotease inhibitors |
| US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
| US5665777A (en) * | 1995-11-14 | 1997-09-09 | Abbott Laboratories | Biphenyl hydroxamate inhibitors of matrix metalloproteinases |
| US6281352B1 (en) | 1995-11-14 | 2001-08-28 | Dupont Pharmaceuticals Company | Macrocyclic compounds as metalloprotease inhibitors |
| ATE205184T1 (de) | 1995-11-23 | 2001-09-15 | British Biotech Pharm | Metalloproteinase inhibitoren |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| DE69719385T2 (de) * | 1996-06-21 | 2003-12-18 | Pharmacia & Upjohn Co., Kalamazoo | Mmp-hemmende thiadiazolylamide |
| US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
| DE69714056T2 (de) | 1996-09-10 | 2003-02-27 | British Biotech Pharmaceuticals Ltd., Cowley | Cytostatische hydroxamsäurederivate |
| US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
| AU5577498A (en) * | 1997-01-31 | 1998-08-25 | Shionogi & Co., Ltd. | Compounds having metalloprotease inhibitory activity |
| US5847148A (en) * | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
| US6576664B1 (en) | 1997-08-18 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis |
| ZA988967B (en) * | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| EP1054877A1 (de) | 1998-02-11 | 2000-11-29 | Du Pont Pharmaceuticals Company | Cyclische sulfonamid-derivate als metallprotease-inhibitoren |
| EP1066273A1 (de) * | 1998-03-25 | 2001-01-10 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitore |
| US6329418B1 (en) | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| FR2780402B1 (fr) * | 1998-06-30 | 2001-04-27 | Adir | Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2344412A1 (en) * | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Thiol compound, their production and use |
| US6114361A (en) * | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| GB9903598D0 (en) * | 1999-02-18 | 1999-04-07 | Univ Manchester | Connective tissue healing |
| AU4180900A (en) | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| WO2000059285A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
| GB9929979D0 (en) * | 1999-12-17 | 2000-02-09 | Darwin Discovery Ltd | Hydroxamic acid derivatives |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| KR20020081465A (ko) * | 2000-03-21 | 2002-10-26 | 더 프록터 앤드 갬블 캄파니 | 헤테로시클릭 측쇄 함유, ｎ-치환된 메탈로프로테아제저해제 |
| EP1265865A2 (de) * | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Difluorbuttersäure-derivate und ihre verwendung als metalloprotease-hemmer |
| KR20030005229A (ko) * | 2000-03-21 | 2003-01-17 | 더 프록터 앤드 갬블 캄파니 | 메탈로프로테아제 저해제를 함유하는 탄소환식 측쇄 |
| US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
| EP1306367B1 (de) | 2000-07-19 | 2007-07-18 | Mitsubishi Pharma Corporation | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| EP1406893B1 (de) | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Bicyclische pyrrolidinverbindungen |
| ITMI20011733A1 (it) * | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| ES2309313T3 (es) | 2002-04-03 | 2008-12-16 | Topotarget Uk Limited | Compuestos del acido carbamico que comprenden un acoplamiento de piperacina como hdac inhibidores. |
| WO2004065354A1 (en) | 2003-01-17 | 2004-08-05 | Topotarget Uk Limited | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors |
| ATE518853T1 (de) | 2005-08-12 | 2011-08-15 | Schering Corp | Verbindungen zur behandlung entzündlicher erkrankungen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
| GB8827308D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
-
1993
- 1993-05-24 US US08/066,832 patent/US5318964A/en not_active Expired - Fee Related
- 1993-05-26 AU AU39816/93A patent/AU659555B2/en not_active Ceased
- 1993-05-28 EP EP93108628A patent/EP0574758B1/de not_active Expired - Lifetime
- 1993-05-28 DK DK93108628T patent/DK0574758T3/da active
- 1993-05-28 ES ES93108628T patent/ES2121896T3/es not_active Expired - Lifetime
- 1993-05-28 DE DE69320869T patent/DE69320869T2/de not_active Expired - Fee Related
- 1993-05-28 AT AT93108628T patent/ATE170840T1/de not_active IP Right Cessation
- 1993-06-02 NZ NZ247765A patent/NZ247765A/en unknown
- 1993-06-04 CZ CZ931081A patent/CZ283373B6/cs unknown
- 1993-06-04 HU HU9301645A patent/HU9301645D0/hu unknown
- 1993-06-07 IL IL105921A patent/IL105921A/en not_active IP Right Cessation
- 1993-06-08 SK SK573-93A patent/SK57393A3/sk unknown
- 1993-06-09 BG BG97857A patent/BG61724B1/bg unknown
- 1993-06-09 MY MYPI93001124A patent/MY108798A/en unknown
- 1993-06-10 NO NO932117A patent/NO932117L/no unknown
- 1993-06-10 IS IS4031A patent/IS4031A/is unknown
- 1993-06-10 JP JP5165228A patent/JPH0776210B2/ja not_active Expired - Fee Related
- 1993-06-10 CN CN93107239A patent/CN1035616C/zh not_active Expired - Fee Related
- 1993-06-10 CA CA002098168A patent/CA2098168A1/en not_active Abandoned
- 1993-06-10 PH PH46328A patent/PH30245A/en unknown
- 1993-06-11 FI FI932692A patent/FI109535B/fi active
-
1994
- 1994-03-17 US US08/214,895 patent/US5447929A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BG97857A (bg) | 1994-12-02 |
| NO932117L (no) | 1993-12-13 |
| CN1083062A (zh) | 1994-03-02 |
| DE69320869D1 (de) | 1998-10-15 |
| MY108798A (en) | 1996-11-30 |
| EP0574758B1 (de) | 1998-09-09 |
| HU9301645D0 (en) | 1993-09-28 |
| JPH0665196A (ja) | 1994-03-08 |
| AU3981693A (en) | 1993-12-16 |
| FI932692L (fi) | 1993-12-12 |
| NZ247765A (en) | 1995-11-27 |
| NO932117D0 (no) | 1993-06-10 |
| SK57393A3 (en) | 1994-05-11 |
| DK0574758T3 (da) | 1999-06-07 |
| JPH0776210B2 (ja) | 1995-08-16 |
| FI932692A0 (fi) | 1993-06-11 |
| US5318964A (en) | 1994-06-07 |
| BG61724B1 (bg) | 1998-04-30 |
| US5447929A (en) | 1995-09-05 |
| CZ283373B6 (cs) | 1998-04-15 |
| ATE170840T1 (de) | 1998-09-15 |
| EP0574758A1 (de) | 1993-12-22 |
| FI109535B (fi) | 2002-08-30 |
| CZ108193A3 (en) | 1994-02-16 |
| CA2098168A1 (en) | 1993-12-12 |
| IL105921A0 (en) | 1993-10-20 |
| IS4031A (is) | 1993-12-12 |
| AU659555B2 (en) | 1995-05-18 |
| IL105921A (en) | 1998-01-04 |
| DE69320869T2 (de) | 1999-04-29 |
| ES2121896T3 (es) | 1998-12-16 |
| CN1035616C (zh) | 1997-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH30245A (en) | Hydroxamic derivatives and pharmaceutical compositions | |
| NO307215B1 (no) | Hydroxamsyre-derivater med tricyklisk substitusjon, medikamenter inneholdende dem, anvendelse av dem og mellomprodukter i fremstilling av dem | |
| HUT71551A (en) | Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives, process for producing them, and pharmaceutical compositions containing them | |
| WO1992015607A3 (en) | Phenyl amidines derivatives useful as platelet aggregation inhibitors | |
| DE69725978D1 (de) | Chalcon-derivate und medikamente die diese enthalten | |
| IL106059A0 (en) | Hydroxamic acid derivatives,their manufacture and pharmaceutical compositions containing them | |
| HUT64023A (en) | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds | |
| WO1994014776A3 (en) | Bicyclic fibrinogen antagonists | |
| ES2103027T3 (es) | Derivados de tienopiridina y composiciones farmaceuticas que los contienen. | |
| PL305457A1 (en) | Galantamine derivatives, method of obtaining them and their application as drugs | |
| DE69706386D1 (de) | 2-Aryl-3-Aminoaryloxynaphthylverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren | |
| EP0878196A4 (de) | Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate | |
| AU643759B2 (en) | Urea derivatives and salts thereof, pharmaceutical compositions containing the same, and methods for producing the same | |
| WO2001022951A3 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis | |
| TW375525B (en) | Inhibitors for morphine-like drug induced emesis containing active components (R)-1-ethyl-4-methyl hexahydro-1H-1,4-diazepine derivatives | |
| MX9303391A (es) | Derivados de acido hidroxamico, procedimiento para su preparcion y medicamento que los contiene. |